title: Circulating very-low-density lipoprotein from subjects with impaired glucose tolerance accelerates adrenocortical cortisol and aldosterone synthesis.
abstract: Apart from their role in cardiovascular homeostasis and immunomodulation, aldosterone and cortisol are also implicated in the pathogenesis of insulin resistance and type 2 diabetes mellitus (T2DM). Furthermore, glycoxidative modifications of lipoproteins are increasingly recognized as an etiological factor for increased cardiovascular morbidity and mortality in prediabetic individuals. The causative relationship between in vivo lipoprotein modifications and steroidogenesis in subjects with impaired glucose tolerance (IGT), however, is not well defined. Therefore, we aimed to investigate the impact of in vivo modified lipoproteins on aldosterone and cortisol release from human adrenocortical H295R cells. Following an oral glucose tolerance test, 20 individuals with normal glucose tolerance (NGT) and 20 IGT subjects were randomly selected from the ongoing PRAEDIAS prevention study in our department. Cells were incubated for 24 h with lipoproteins isolated from NGT and IGT individuals and aldosterone and cortisol release was measured in the supernatants. VLDL induced a greater stimulating effect on adrenocortical aldosterone and cortisol release compared to HDL and LDL. Moreover, IGT-VLDL evoked a significantly higher effect (p<0.05) on hormone release than NGT-VLDL. Incubation of cells with in vitro modified lipoproteins and specific pharmacological inhibitors suggests that VLDL presumably recruits ERK1/2 as one of the downstream effectors of Jak-2. In summary, in vivo modified VLDL are able to promote prediabetic hormonal dysregulation by modulating adrenocortical steroidogenesis via Jak-2-ERK dependent pathway.
authors.affiliation: Department of Internal Medicine 3, Carl Gustav Carus Medical School, Technical University of Dresden, Dresden, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Saha
authors.forename: P E H
authors.initials: PE
authors.lastname: Schwarz
authors.forename: S
authors.initials: S
authors.lastname: Bergmann
authors.forename: S R
authors.initials: SR
authors.lastname: Bornstein
authors.forename: J
authors.initials: J
authors.lastname: Graessler
authors.forename: S
authors.initials: S
authors.lastname: Kopprasch
mesh_terms: D000302:Adrenal Cortex / Q000187:drug effects / Q000378:metabolism*; D000368:Aged; D000450:Aldosterone / Q000378:metabolism*; D002460:Cell Line; D018149:Glucose Intolerance / Q000097:blood / Q000378:metabolism* / Q000503:physiopathology; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D006854:Hydrocortisone / Q000378:metabolism*; D006943:Hyperglycemia / Q000209:etiology; D008075:Lipoproteins, HDL / Q000097:blood / Q000378:metabolism; D008077:Lipoproteins, LDL / Q000097:blood / Q000378:metabolism; D008079:Lipoproteins, VLDL / Q000097:blood / Q000378:metabolism*; D020935:MAP Kinase Signaling System / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010766:Phosphorylation / Q000187:drug effects; D011236:Prediabetic State / Q000097:blood / Q000378:metabolism / Q000503:physiopathology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D000450:Aldosterone; D006442:Glycated Hemoglobin; D006854:Hydrocortisone; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D047428:Protein Kinase Inhibitors; C517652:hemoglobin A1c protein, human